[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @GilaMonstrum Noumena Analysis Noumena Analysis posts on X about $vktx, $lly, $mtsr, $pfe the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1494036559502401539/interactions)  - X Week XXXXX +20,264% - X Month XXXXXX -XX% - X Months XXXXXXX -XX% - X Year XXXXXXX +167% ### Mentions: XX [#](/creator/twitter::1494036559502401539/posts_active)  - X Week XX +267% - X Month XX +26% - X Months XX -XX% - X Year XXX +331% ### Followers: XXXXX [#](/creator/twitter::1494036559502401539/followers)  - X Week XXXXX +2.10% - X Month XXXXX +5.90% - X Months XXXXX +53% - X Year XXXXX +221% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1494036559502401539/influencer_rank)  ### Social Influence [#](/creator/twitter::1494036559502401539/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXXX% **Social topic influence** [$vktx](/topic/$vktx) #20, [$lly](/topic/$lly) #17, [$mtsr](/topic/$mtsr) #8, [$pfe](/topic/$pfe) #292, [weight loss](/topic/weight-loss) #1029, [investment](/topic/investment) 3.85%, [$alt](/topic/$alt) 3.85%, [alt](/topic/alt) 3.85%, [rates](/topic/rates) 3.85%, [novo](/topic/novo) XXXX% **Top accounts mentioned or mentioned by** [@bioinvestor24](/creator/undefined) [@knielsen2000](/creator/undefined) [@mufaso7](/creator/undefined) [@doctor_salomon](/creator/undefined) [@lnginvestor](/creator/undefined) [@sportsbios](/creator/undefined) [@fluffer9](/creator/undefined) [@lipa0902](/creator/undefined) [@doctorsalomon](/creator/undefined) [@biopharmiq](/creator/undefined) [@corleonedon77](/creator/undefined) [@godsavecharles](/creator/undefined) [@cryptobiotech](/creator/undefined) [@cyrpto2021](/creator/undefined) [@pgainz96934](/creator/undefined) [@bavariaron](/creator/undefined) [@sports_bios](/creator/undefined) **Top assets mentioned** [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Eli Lilly and Company (LLY)](/topic/$lly) [Metsera, Inc. Common Stock (MTSR)](/topic/$mtsr) [Pfizer, Inc. (PFE)](/topic/$pfe) [AltLayer (ALT)](/topic/$alt) [Novo-Nordisk (NVO)](/topic/$nvo) ### Top Social Posts [#](/creator/twitter::1494036559502401539/posts) --- Top posts by engagements in the last XX hours "How would $LLY tirzepatide compare with $VKTX sc VK2735 if both are titrated the same To answer this question I built a PK/PD model using the methodology briefly described below: X. Simulate single dose PK for each drug from published parameters (T1/2 and Tmax are reported in the literature/ corporate decks. F=80% for TZP I assumed the same for VK 2735). X. Convert plasma profiles to cumulative exposure (AUC) using the trapezoidal rule. X. Plot AUC to weight loss data from SURMOUNT-1 and VENTURE. X. Fit an individual Hill model for VK and TZP with an assumed Emax of XX% for both drugs." [X Link](https://x.com/GilaMonstrum/status/1979950271007699262) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T16:38Z 1934 followers, 13.3K engagements "@Doctor_Salomon @LNG_Investor_ I haven't seen data as good as tzp in Surmount X with anything else so far" [X Link](https://x.com/GilaMonstrum/status/1979957364208840881) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T17:06Z 1933 followers, XXX engagements "I understand you want to protect your investment but highlighting $VKTX oral VK 2735 d/c while overlooking $ALT challenging obesity d/c rates is a bit funny tbh. VK2735 has oral and sc forms the higher d/c occurred in the P2 oral trial. Pemvis real competitor would be sc VK2735 so.yeah" [X Link](https://x.com/GilaMonstrum/status/1980135515350339800) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T04:54Z 1934 followers, 1168 engagements "@GodSaveCharles "Has yet surpassed" as in "to date". I did not make any assumptions on future trials I guess Novo already made that assumption" [X Link](https://x.com/GilaMonstrum/status/1980160040981172520) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T06:31Z 1933 followers, XXX engagements "@bioinvestor24 Clinically it seems to be similar to $LLY tirzepatide but the studies are too short (4 weeks). I wasn't impressed by their P2 data vs semaglutide X mg in diabetics. Maybe it is wishful thinking but I am starting to see a pattern here:" [X Link](https://x.com/GilaMonstrum/status/1929625513695297607) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-06-02T19:45Z 1925 followers, 4480 engagements "$MTSR $PFE Finally released the Phase 2b VESPER X and VESPER X results and frankly their PR is confusing and selectively framed. I have a headache after reading it. $VKTX BL take notes this is a masterclass in how to spin your data. Vesper X had X arms (MET-097i XXX mg XXX mg XXX mg and XXX mg) QW without titration. The efficacy they reported is pbo-adjusted and they withheld the actual placebo WL data. This is a huge red flag given that in their previous trials the placebo arm gains weight (uniquely as far as Ive seen - see pic). By hiding placebo here they can inflate the headline and claim" [X Link](https://x.com/GilaMonstrum/status/1972908597232202073) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T06:17Z 1928 followers, 15.3K engagements "@bioinvestor24 I just cant get over the fact that $PFE said they reviewed this data and felt "comfortable". It practically screams shady how can they feel confortable to go against $LLY ans $NVO with this" [X Link](https://x.com/GilaMonstrum/status/1973027948103102943) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T14:11Z 1928 followers, 4666 engagements "@bioinvestor24 $pfe is up $mtsr is up $vktx is down" [X Link](https://x.com/GilaMonstrum/status/1973028385040519444) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-30T14:13Z 1928 followers, XXX engagements "@LNG_Investor_ yeah.its both misunderstood and undervalued. The thesis has gotten complex with a crowded field you cant tell agents apart without going deep into the details" [X Link](https://x.com/GilaMonstrum/status/1979952006916964389) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T16:45Z 1931 followers, XXX engagements "@Doctor_Salomon @LNG_Investor_ My base case: the XX mg arm is at least non-inferior to TZP on weight loss with better safety given the slow titration (starting at XXX mg). I expect the XXXX mg arm to outperform TZP XX mg on both weight loss and safety" [X Link](https://x.com/GilaMonstrum/status/1979961268753629538) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-19T17:22Z 1932 followers, XXX engagements "Has anyone seen the $MTSR discontinuation rates for any of their drugs $VKTX" [X Link](https://x.com/GilaMonstrum/status/1971189510928322622) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-09-25T12:26Z 1933 followers, 4602 engagements ""At XX weeks in MOMENTUM mean weight loss reached 1015.6 % without titration and with sub-5 % discontinuations at mid-dose which is extremely impressive for a compound with NO dose escalation" How can you claim sub X% discontinuations with mid doses in Momentum when the XXX mg dose showed a XXXX% d/c and the XXX mg dose showed d/c of XXXX% Also if you include the weight loss of XXXX% for the XXX mg (titrated) dose make sure you also include the d/c rate for that dose (which was a staggering 42.3%). Otherwise it is a WL between XXXX% and XXXX% (8.1% and X% PBO adjusted) at XX weeks with d/c" [X Link](https://x.com/GilaMonstrum/status/1980174877756686376) [@GilaMonstrum](/creator/x/GilaMonstrum) 2025-10-20T07:30Z 1933 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@GilaMonstrum Noumena Analysis
Noumena Analysis posts on X about $vktx, $lly, $mtsr, $pfe the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +20,264%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +167%
Mentions: XX #
- X Week XX +267%
- X Month XX +26%
- X Months XX -XX%
- X Year XXX +331%
Followers: XXXXX #
- X Week XXXXX +2.10%
- X Month XXXXX +5.90%
- X Months XXXXX +53%
- X Year XXXXX +221%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXXX% finance XXXX%
Social topic influence $vktx #20, $lly #17, $mtsr #8, $pfe #292, weight loss #1029, investment 3.85%, $alt 3.85%, alt 3.85%, rates 3.85%, novo XXXX%
Top accounts mentioned or mentioned by @bioinvestor24 @knielsen2000 @mufaso7 @doctor_salomon @lnginvestor @sportsbios @fluffer9 @lipa0902 @doctorsalomon @biopharmiq @corleonedon77 @godsavecharles @cryptobiotech @cyrpto2021 @pgainz96934 @bavariaron @sports_bios
Top assets mentioned Viking Therapeutics, Inc (VKTX) Eli Lilly and Company (LLY) Metsera, Inc. Common Stock (MTSR) Pfizer, Inc. (PFE) AltLayer (ALT) Novo-Nordisk (NVO)
Top Social Posts #
Top posts by engagements in the last XX hours
"How would $LLY tirzepatide compare with $VKTX sc VK2735 if both are titrated the same To answer this question I built a PK/PD model using the methodology briefly described below: X. Simulate single dose PK for each drug from published parameters (T1/2 and Tmax are reported in the literature/ corporate decks. F=80% for TZP I assumed the same for VK 2735). X. Convert plasma profiles to cumulative exposure (AUC) using the trapezoidal rule. X. Plot AUC to weight loss data from SURMOUNT-1 and VENTURE. X. Fit an individual Hill model for VK and TZP with an assumed Emax of XX% for both drugs."
X Link @GilaMonstrum 2025-10-19T16:38Z 1934 followers, 13.3K engagements
"@Doctor_Salomon @LNG_Investor_ I haven't seen data as good as tzp in Surmount X with anything else so far"
X Link @GilaMonstrum 2025-10-19T17:06Z 1933 followers, XXX engagements
"I understand you want to protect your investment but highlighting $VKTX oral VK 2735 d/c while overlooking $ALT challenging obesity d/c rates is a bit funny tbh. VK2735 has oral and sc forms the higher d/c occurred in the P2 oral trial. Pemvis real competitor would be sc VK2735 so.yeah"
X Link @GilaMonstrum 2025-10-20T04:54Z 1934 followers, 1168 engagements
"@GodSaveCharles "Has yet surpassed" as in "to date". I did not make any assumptions on future trials I guess Novo already made that assumption"
X Link @GilaMonstrum 2025-10-20T06:31Z 1933 followers, XXX engagements
"@bioinvestor24 Clinically it seems to be similar to $LLY tirzepatide but the studies are too short (4 weeks). I wasn't impressed by their P2 data vs semaglutide X mg in diabetics. Maybe it is wishful thinking but I am starting to see a pattern here:"
X Link @GilaMonstrum 2025-06-02T19:45Z 1925 followers, 4480 engagements
"$MTSR $PFE Finally released the Phase 2b VESPER X and VESPER X results and frankly their PR is confusing and selectively framed. I have a headache after reading it. $VKTX BL take notes this is a masterclass in how to spin your data. Vesper X had X arms (MET-097i XXX mg XXX mg XXX mg and XXX mg) QW without titration. The efficacy they reported is pbo-adjusted and they withheld the actual placebo WL data. This is a huge red flag given that in their previous trials the placebo arm gains weight (uniquely as far as Ive seen - see pic). By hiding placebo here they can inflate the headline and claim"
X Link @GilaMonstrum 2025-09-30T06:17Z 1928 followers, 15.3K engagements
"@bioinvestor24 I just cant get over the fact that $PFE said they reviewed this data and felt "comfortable". It practically screams shady how can they feel confortable to go against $LLY ans $NVO with this"
X Link @GilaMonstrum 2025-09-30T14:11Z 1928 followers, 4666 engagements
"@bioinvestor24 $pfe is up $mtsr is up $vktx is down"
X Link @GilaMonstrum 2025-09-30T14:13Z 1928 followers, XXX engagements
"@LNG_Investor_ yeah.its both misunderstood and undervalued. The thesis has gotten complex with a crowded field you cant tell agents apart without going deep into the details"
X Link @GilaMonstrum 2025-10-19T16:45Z 1931 followers, XXX engagements
"@Doctor_Salomon @LNG_Investor_ My base case: the XX mg arm is at least non-inferior to TZP on weight loss with better safety given the slow titration (starting at XXX mg). I expect the XXXX mg arm to outperform TZP XX mg on both weight loss and safety"
X Link @GilaMonstrum 2025-10-19T17:22Z 1932 followers, XXX engagements
"Has anyone seen the $MTSR discontinuation rates for any of their drugs $VKTX"
X Link @GilaMonstrum 2025-09-25T12:26Z 1933 followers, 4602 engagements
""At XX weeks in MOMENTUM mean weight loss reached 1015.6 % without titration and with sub-5 % discontinuations at mid-dose which is extremely impressive for a compound with NO dose escalation" How can you claim sub X% discontinuations with mid doses in Momentum when the XXX mg dose showed a XXXX% d/c and the XXX mg dose showed d/c of XXXX% Also if you include the weight loss of XXXX% for the XXX mg (titrated) dose make sure you also include the d/c rate for that dose (which was a staggering 42.3%). Otherwise it is a WL between XXXX% and XXXX% (8.1% and X% PBO adjusted) at XX weeks with d/c"
X Link @GilaMonstrum 2025-10-20T07:30Z 1933 followers, XXX engagements